Trial Population Was One Reason For Pulling Surufatinib EU Filing

 
• By Neena Brizmohun
  
A path forward
Hutchmed is in discussions with EU and US regulators on the path forward • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Geography